Karyopharm Therapeutics’ (KPTI) “Outperform” Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has a $3.00 price objective on the stock.

A number of other research firms also recently weighed in on KPTI. Piper Sandler raised their target price on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. StockNews.com downgraded Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Finally, HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Karyopharm Therapeutics in a report on Thursday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $5.00.

Karyopharm Therapeutics Stock Down 1.9 %

Shares of KPTI stock opened at $0.60 on Thursday. The firm has a fifty day moving average of $0.66 and a 200-day moving average of $0.76. Karyopharm Therapeutics has a 12-month low of $0.53 and a 12-month high of $1.70. The company has a market capitalization of $75.54 million, a price-to-earnings ratio of -0.59 and a beta of 0.06.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Wednesday, February 19th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.02. The firm had revenue of $30.54 million for the quarter, compared to the consensus estimate of $30.29 million. On average, equities analysts expect that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC increased its position in Karyopharm Therapeutics by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 1,392,314 shares of the company’s stock valued at $942,000 after buying an additional 36,922 shares in the last quarter. Silverarc Capital Management LLC boosted its holdings in Karyopharm Therapeutics by 6.7% in the fourth quarter. Silverarc Capital Management LLC now owns 595,990 shares of the company’s stock worth $403,000 after acquiring an additional 37,524 shares in the last quarter. Velan Capital Investment Management LP bought a new stake in shares of Karyopharm Therapeutics during the fourth quarter valued at approximately $27,000. Two Sigma Advisers LP raised its position in shares of Karyopharm Therapeutics by 145.5% during the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock worth $52,000 after purchasing an additional 45,400 shares during the period. Finally, Focus Partners Wealth bought a new position in shares of Karyopharm Therapeutics in the 4th quarter worth $31,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).